# Non-Alcoholic Steatohepatitis Market 2024-2032, Size, Share Analysis and Forecast
IMARC Group's report titled "Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), Sales Channel (Hospital Pharmacy, Online Providers, Retail Pharmacy), End User (Hospitals, Clinics, Homecare Settings), and Region 2024-2032". The global [non-alcoholic steatohepatitis market](https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market) size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample

Factors Affecting the Growth of the Non-Alcoholic Steatohepatitis Industry:

Rising Obesity Rates:

Obesity is closely associated with the development of NASH. Excessive fat accumulation in the liver, which is common in obese people, can lead to liver disease developing into NASH. As a result, healthcare providers and patients are increasingly focused on addressing NASH, creating a growing market for diagnostic testing, treatments, and treatments. Obese individuals with NASH often require specialized medical attention and treatment. As more people become obese and subsequently develop NASH, there is a greater need for healthcare providers to provide effective treatments, medications, and interventions. This is driving demand for medicines and medical procedures related to NASH management.

Awareness and Diagnosis:

As awareness of NASH increases, more emphasis is placed on early detection and diagnosis. As more individuals and healthcare professionals recognize the signs and risk factors for NASH, there is a greater chance of identifying the condition in its early stages. This is driving increased demand for NASH-specific diagnostic tools and tests, including imaging techniques and blood markers. As awareness improves, the incidence of NASH is increasing. Healthcare providers are better equipped to diagnose NASH, so more cases are being documented. This increase in diagnosed cases increases the overall demand for NASH-related healthcare services, medications, and interventions.

Aging Population:

NASH is more commonly diagnosed in older people. As the global population ages, the number of individuals at higher risk of developing NASH naturally increases. These demographic changes lead to an increase in the potential NASH patient pool, contributing to market growth. Elderly people often have comorbidities such as diabetes, hypertension, and hyperlipidemia, which are known risk factors for NASH. The presence of these conditions in the aging population increases the likelihood of developing NASH, increasing the demand for NASH-related healthcare services and treatments.

Leading Companies Operating in the Global Non-Alcoholic Steatohepatitis Industry:

Algernon Pharmaceuticals
Galmed Pharmaceuticals Ltd
Intercept Pharmaceuticals Inc.
Zydus Lifesciences Limited

Non-Alcoholic Steatohepatitis Market Report Segmentation:

By Drug Type:

Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib
Cenicriviroc
Others

Vitamin E and pioglitazone accounted for the largest segment due to their widespread availability and physician recommendation, as well as their effectiveness in managing NASH-related symptoms and complications.

By Disease Cause:

Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity

Obesity accounted for the largest market share as it is a major risk factor for NASH, and the increasing prevalence of obesity globally is increasing the demand for NASH-related products and services.

By Sales Channel:

Hospital Pharmacy
Online Providers
Retail Pharmacy

Retail pharmacies clearly dominate the market due to their accessibility and convenience to patients seeking over-the-counter (OTC) medications and supplements commonly used in the management of NASH.

By End User:

Hospitals
Clinics
Homecare Settings

The clinic holds the largest market share and attracts a significant patient population, which can be attributed to the essential healthcare facilities provided by the clinic for NASH diagnosis, treatment and ongoing patient care.

Regional Insights:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

North America holds a leading position in the non-alcoholic steatohepatitis market due to high prevalence of NASH and advanced healthcare infrastructure.

Global Non-Alcoholic Steatohepatitis Market Trends:

There is increasing emphasis on developing accurate and non-invasive diagnostic tools for NASH. Innovations in imaging techniques, blood biomarkers, and methods for assessing liver fibrosis are improving early detection rates.

Pharmaceutical companies are actively researching and developing new treatments and drugs for NASH.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [e-mail]

Tel No:(D) [phone]

United States: [phone] | United Kingdom: [phone]